Omeros What They 'Knee'-ded: Mixed Phase III, New Trial Due

By Randy OsborneStaff Writer

Friday, December 28, 2012

Equivocal results from its first pivotal Phase III trial with OMS103HP in knee surgery shaved Omeros Corp.'s stock, but gave the company a roadmap for the next study, which will use postoperative pain  a secondary endpoint, met in the latest experiment  as the primary outcome goal.